Adherence, safety, efficacy – three pillars of hypertension treatment with fixed dose combinations
https://doi.org/10.38109/2075-082X-2024-4-121-127
Abstract
Objective. ToGlobally more than 1.4 billion people have hypertension, of whom less than 15% have their blood pressure appropriately controlled (BP), and that is the leading cause of death globally. In low- and middle-income countries, more than 70% of the treated patients have uncontrolled hypertension. One of the major reasons for poor control is reliable patient adherence to treatment. fixed-dose combinations, which incorporate two antihypertensive drugs or more can improve control rates BP without increasing the risk of adverse events, and can thereby prevent complications of uncontrolled hypertension.
The advantages of fixed combinations from Canonpharma Production are proven bioequivalence to reference drugs, good tolerability, ease of use and lower cost compared to original drugs. fixed combinations from Canonpharma Production are represented by several two- and three-component combinations of antihypertensive drugs in various dosages, which help physician to prescribe and escalate antihypertensive therapy.
About the Author
N. V. BlinovaRussian Federation
Nataliya V. Blinova, Cand. of Sci. (Med.), Senior Researcher of Department of Hypertension, a.L. Myasnikov Institute of Clinical Cardiology
St. academician Chazova, 15 a, Moscow 121552, tel. +7 (495) 414-61-86
References
1. Roth Ga, Mensah Ga, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk factors, 1990- 2019: Update from the GBD 2019 Study [published correction appears in J am Coll Cardiol. 2021 apr 20;77(15):1958-1959. https://doi.org/10.1016/j.jacc.2021.02.039]. J am Coll Cardiol. 2020;76(25):2982- 3021. https://doi.org/10.1016/j.jacc.2020.11.010
2. Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROaSPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824-835. https://doi.org/10.1177/2047487318825350
3. Balanova Yu.a., Drapkina O.M., Kutsenko V.a., et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-Rf3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3785
4. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHaNES III Linked Mortality Study. Sci Rep. 2018;8(1):9418. Published 2018 Jun 20. https://doi.org/10.1038/s41598-018-27377-2
5. Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H; Investigators’ network. Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour ambulatory Blood Pressure: The JaMP Study. Hypertension. 2021;78(6):1781-1790. https://doi.org/10.1161/HYPERTENSIONaHa.121.18198
6. Chowdhury R, Khan H, Heydon E, et al. adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-2948. https://doi.org/10.1093/eurheartj/eht295
7. Mazzaglia G, ambrosioni E, alacqua M, et al. adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598- 1605. https://doi.org/10.1161/CIRCULaTIONaHa.108.830299
8. Rotar O.P., Ilyanova I.N., Boyarinova M.a. 2023 all-Russian screening for hypertension: results. Russian Journal of Cardiology. 2024;29(5):5931. (In Russ.) EDN: EMCJRB. https://doi.org/10.15829/1560-4071-2024-5931
9. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal association (ERa) [published correction appears in J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/HJH.0000000000003621]. J Hypertens. 2023;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480
10. Chazova I.E., Zhernakova Yu.V. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertension. 2019;16(1):6- 31. (In Russ.) https://doi.org/10.26442/2075082X.2019.1.190179
11. Chazova I.E., Ratova L.G. Combination therapy of arterial hypertension. In the book: Guide to arterial hypertension. Edited by acad. E.I. Chazov, prof. I.E. Chazova. M.: Media Medica, 2005, pp. 655-677. (in Russ.)
12. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens. 1999;13(7):477-483. https://doi.org/10.1038/sj.jhh.1000855
13. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. arch Intern Med. 1996;156(17):1969-1978. PMID: 8823150
14. Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixeddose combination. Clin Drug Investig. 2013;33(7):469-476. https://doi.org/10.1007/s40261-013-0086-9
15. Gupta aK, arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407. https://doi.org/10.1161/HYPERTENSIONaHa.109.139816
16. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012;15(5):897-905. https://doi.org/10.3111/13696998.2012.689792
17. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 feb 1;40(5):475. https://doi.org/10.1093/eurheartj/ehy686]. Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
18. Kisliak O.a., Zhernakova J.V., aksenova a.V., Chazova I.E. Russian medical society expert consensus on arterial hypertension: use of fixed combinations in the treatment of patients with arterial hypertension. Systemic Hypertension. 2024;21(1):5-13. (In Russ.) https://doi.org/10.38109/2075-082X-2024-1-5-13
19. Kobalava Zh.D., Konradi a.O., Nedogoda S.V., Shlyakhto E.V., et al. arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
20. Schmieder RE, Wassmann S, Predel HG, et al. Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced all-Cause Mortality in Hypertensive Patients With Use of SinglePill Combinations: Results from the STaRT-Study. Hypertension. 2023;80(5):1127-1135. https://doi.org/10.1161/HYPERTENSIONaHa.122.20810
21. Derington CG, Cohen JB, Bress aP. Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations. J Hum Hypertens. 2020;34(9):617-623. https://doi.org/10.1038/s41371-020-0340-6
22. Sarzani R, Laureti G, Gezzi a, Spannella f, Giulietti f. Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Ther adv Chronic Dis. 2022;13:20406223221102754. Published 2022 Jun 24. https://doi.org/10.1177/20406223221102754
23. Calhoun Da, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32-39. https://doi.org/10.1161/HYPERTENSIONaHa.109.131300
24. Allemann Y, fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after Single Therapy (EX-faST) study. J Clin Hypertens (Greenwich). 2008;10(3):185-194. https://doi.org/10.1111/j.1751-7176.2008.07516.x
25. Jamerson K, Bakris GL, Dahlöf B, et al. Exceptional early blood pressure control rates: the aCCOMPLISH trial. Blood Press. 2007;16(2):80-86. https://doi.org/10.1080/08037050701395571
26. Lipski D, Marzyńska D, Sytek P, et al. Obesity in Hypertensive Patients Is Characterized by a Dawn Phenomenon in Systolic Blood Pressure Values and Variability. J Clin Med. 2024;13(2):371. Published 2024 Jan 10. https://doi.org/10.3390/jcm13020371
27. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTaRGET (ONgoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial). J am Coll Cardiol. 2012;59(1):74-83. https://doi.org/10.1016/j.jacc.2011.09.040
28. Lauffenburger JC, Landon JE, fischer Ma. Effect of Combination Therapy on adherence among US Patients Initiating Therapy for Hypertension: a Cohort Study. J Gen Intern Med. 2017;32(6):619-625. https://doi.org/10.1007/s11606-016-3972-z
Review
For citations:
Blinova N.V. Adherence, safety, efficacy – three pillars of hypertension treatment with fixed dose combinations. Systemic Hypertension. 2024;21(4):121-127. (In Russ.) https://doi.org/10.38109/2075-082X-2024-4-121-127